Literature DB >> 6506755

Role of the intestinal microflora in clonazepam metabolism in the rat.

G W Elmer, R P Remmel.   

Abstract

The metabolism of clonazepam was studied in vitro and in vivo using germ-free and ex-germ-free rats. Incubation of clonazepam with rat-intestinal lumen contents gave nearly complete reduction of clonazepam to 7-aminoclonazepam. Rat-hepatic microsomes also reduced clonazepam but only under anaerobic conditions. Aerobic microsomal incubations gave 3-hydroxyclonazepam as the predominant metabolite. Both aerobic and anaerobic microsomal metabolism were induced by phenobarbital. Carbamazepine pretreatment significantly induced only 3-hydroxylation slightly; whereas beta-naphthoflavone had no significant effect. Extensive biliary disposition of hydroxylated clonazepam metabolites into the gut occurred. Only very low levels of clonazepam were found in bile. Using a linked-rat procedure enterohepatic recirculation of biliary metabolites was demonstrated and suppression (antibiotic treatment) or absence (germ-free) of the gut microflora nearly eliminated recycling. Following oral administration of [14C]clonazepam to germ-free rats, reduced metabolites accounted for 15% of the radioactivity in the urine, with over 70% of the 14C attributed to a phenolic clonazepam metabolite. In contrast 77% of the recovered metabolites were derived from nitroreduction in the same animals following acquisition of an intestinal microflora; 7-acetamidoclonazepam was the major metabolite in these ex-germ-free animals. These studies show that clonazepam metabolism is primarily reductive in the presence of gut flora and oxidative in its absence.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6506755     DOI: 10.3109/00498258409151481

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  9 in total

Review 1.  Drug-gut microbiota interactions: implications for neuropharmacology.

Authors:  Jacinta Walsh; Brendan T Griffin; Gerard Clarke; Niall P Hyland
Journal:  Br J Pharmacol       Date:  2018-06-28       Impact factor: 8.739

2.  Separating host and microbiome contributions to drug pharmacokinetics and toxicity.

Authors:  Michael Zimmermann; Maria Zimmermann-Kogadeeva; Rebekka Wegmann; Andrew L Goodman
Journal:  Science       Date:  2019-02-07       Impact factor: 47.728

Review 3.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity.

Authors:  Ian D Wilson; Jeremy K Nicholson
Journal:  Transl Res       Date:  2016-08-13       Impact factor: 7.012

Review 4.  Developing a metagenomic view of xenobiotic metabolism.

Authors:  Henry J Haiser; Peter J Turnbaugh
Journal:  Pharmacol Res       Date:  2012-08-09       Impact factor: 7.658

5.  Insights from pharmacokinetic models of host-microbiome drug metabolism.

Authors:  Maria Zimmermann-Kogadeeva; Michael Zimmermann; Andrew L Goodman
Journal:  Gut Microbes       Date:  2019-09-29

Review 6.  Towards a mechanistic understanding of reciprocal drug-microbiome interactions.

Authors:  Michael Zimmermann; Kiran Raosaheb Patil; Athanasios Typas; Lisa Maier
Journal:  Mol Syst Biol       Date:  2021-03       Impact factor: 11.429

Review 7.  From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways.

Authors:  G B Rogers; D J Keating; R L Young; M-L Wong; J Licinio; S Wesselingh
Journal:  Mol Psychiatry       Date:  2016-04-19       Impact factor: 15.992

Review 8.  Flux, Impact, and Fate of Halogenated Xenobiotic Compounds in the Gut.

Authors:  Siavash Atashgahi; Sudarshan A Shetty; Hauke Smidt; Willem M de Vos
Journal:  Front Physiol       Date:  2018-07-10       Impact factor: 4.566

Review 9.  Pharmacological Efficacy/Toxicity of Drugs: A Comprehensive Update About the Dynamic Interplay of Microbes.

Authors:  Juan Antonio Gimenez-Bastida; Lucia Martinez Carreras; Angela Moya-Pérez; José Moisés Laparra Llopis
Journal:  J Pharm Sci       Date:  2017-10-26       Impact factor: 3.534

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.